Pinto J C, Potié F, Rice K C, Boring D, Johnson M R, Evans D M, Wilken G H, Cantrell C H, Howlett A C
Laboratory of Medicinal Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892.
Mol Pharmacol. 1994 Sep;46(3):516-22.
The cannabinoid receptor in brain (CB1) specifically binds delta 9-tetrahydrocannabinol, the predominant central nervous system-active component of marijuana. An eicosanoid found in brain, N-(2-hydroxyethyl)arachidonylamide (anandamide), binds to CB1 with similar affinity. This report considers structure-activity requirements for a series of novel amides and rigid hairpin conformations typified by N-(2-hydroxyethyl)prostaglandin amides, assayed with phenylmethylsulfonyl fluoride inactivation of esterases/amidases. Arachidonyl esters were 30-fold less potent than N-(2-hydroxyethyl)arachidonylamide, showing a rank order of potency of methyl = ethyl > propyl = isopropyl. Within the N-(hydroxyalkyl)arachidonylamide series, a one-carbon increase in chain length increased the potency 2-fold, but continued extension decreased affinity. Substituting the amide for the N-(2-hydroxyethyl)amide function produced a 4-fold loss of affinity. The N-(propyl)-, N-(butyl)-, and N-(benzyl)arachidonylamide derivatives exhibited a 3-fold increase, no change, and a 5-fold decrease, respectively, in affinity, compared with N-(2-hydroxyethyl)arachidonylamide. Both the methoxy ether and the formamide derivatives suffered > 20-fold loss of potency, compared with N-(2-hydroxyethyl)arachidonylamide. N-(2-Aminoethyl)arachidonylamide interacted poorly with CB1. At 100 microM, N-(2-hydroxyethyl)amide analogs of prostaglandin E2, A2, B2, and B1 failed to alter [3H]CP55940 binding to CB1. N-(2-Hydroxyethyl)arachidonylamide inhibited adenylate cyclase with lesser potency but with similar efficacy, compared with desacetyllevonantradol. Extending the length of the hydroxyalkyl moiety by one carbon increased the apparent potency by 1 order of magnitude. The N-(propyl) derivative exhibited a 5-fold greater potency than did the N-(2-hydroxyethyl) analog. It appears that the bulk and length of the moiety appended to arachidonic acid are more important determinants of affinity for CB1 than is hydrogen-bonding capability.
大脑中的大麻素受体(CB1)特异性结合δ9 - 四氢大麻酚,它是大麻中主要的中枢神经系统活性成分。在大脑中发现的一种类花生酸,N -(2 - 羟乙基)花生四烯酸酰胺(花生四烯乙醇胺),以相似的亲和力与CB1结合。本报告通过苯甲基磺酰氟对酯酶/酰胺酶的失活作用,研究了一系列新型酰胺以及以N -(2 - 羟乙基)前列腺素酰胺为代表的刚性发夹构象的构效关系。花生四烯酸酯的效力比N -(2 - 羟乙基)花生四烯酸酰胺低30倍,其效力顺序为甲基 = 乙基 > 丙基 = 异丙基。在N -(羟烷基)花生四烯酸酰胺系列中,链长增加一个碳原子会使效力增加2倍,但继续延长则会降低亲和力。用酰胺取代N -(2 - 羟乙基)酰胺官能团会导致亲和力损失4倍。与N -(2 - 羟乙基)花生四烯酸酰胺相比,N -(丙基) - 、N -(丁基) - 和N -(苄基)花生四烯酸酰胺衍生物的亲和力分别增加3倍、不变和降低5倍。与N -(2 - 羟乙基)花生四烯酸酰胺相比,甲氧基醚和甲酰胺衍生物的效力损失均超过20倍。N -(2 - 氨基乙基)花生四烯酸酰胺与CB1的相互作用较弱。在100微摩尔浓度下,前列腺素E2、A2、B2和B1的N -(2 - 羟乙基)酰胺类似物未能改变[3H]CP55940与CB1的结合。与去乙酰左啡诺相比,N -(2 - 羟乙基)花生四烯酸酰胺抑制腺苷酸环化酶的效力较低,但效果相似。将羟烷基部分的长度增加一个碳原子会使表观效力提高1个数量级。N -(丙基)衍生物的效力比N -(2 - 羟乙基)类似物高5倍。似乎连接在花生四烯酸上的部分的体积和长度对与CB1的亲和力来说,比氢键结合能力更重要。